Stempoint Capital’s AnaptysBio ANAB Stock Holding History

Stempoint Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-269,548	Closed	-$6.07M	–	45
2024 Q1	$6.07M	Buy	269,548 +224,548	+499%	+$5.32M	1.6%	19
2023 Q4	$964K	Buy	+45,000	New	+$776K	0.26%	58

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Stempoint Capital's ANAB Position: Q2 2024 in Review

Stempoint Capital sold out of AnaptysBio (ANAB) in Q2 2024, closing a stake of 269,548 shares — an estimated $6.07M sold.

Stempoint Capital first reported a position in ANAB in Q4 2023 and held it in 2 quarters. The position peaked at $6.07M in Q1 2024. 135 funds tracked by Wall St. Rank hold ANAB as of Q2 2024.

Stempoint Capital reported no remaining AnaptysBio position as of Q2 2024 after selling out during the quarter.
Stempoint Capital sold 269,548 AnaptysBio shares in Q2 2024, an estimated $6.07M.
Stempoint Capital first reported a position in AnaptysBio in Q4 2023 and held it in 2 quarters.
Stempoint Capital's AnaptysBio position peaked at $6.07M in Q1 2024.
135 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2024.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.